Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sharon Benzeno Sells 11,034 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Sharon Benzeno sold 11,034 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $21.00, for a total transaction of $231,714.00. Following the completion of the transaction, the insider owned 272,751 shares in the company, valued at $5,727,771. The trade was a 3.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sharon Benzeno also recently made the following trade(s):

• On Monday, June 29th, Sharon Benzeno sold 154,768 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $21.14, for a total transaction of $3,271,795.52.

Adaptive Biotechnologies Trading Up 0.2%

ADPT traded up $0.05 during trading on Tuesday, hitting $21.45. 3,421,196 shares of the company’s stock were exchanged, compared to its average volume of 3,848,816. Adaptive Biotechnologies Corporation has a 1 year low of $9.96 and a 1 year high of $21.64. The stock has a 50 day moving average price of $15.66 and a 200 day moving average price of $15.74. The firm has a market cap of $3.43 billion, a P/E ratio of -65.00 and a beta of 2.15.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The business’s revenue for the quarter was up 35.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.20) EPS. Analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Adaptive Biotechnologies

Institutional investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd purchased a new position in Adaptive Biotechnologies in the 4th quarter valued at about $28,000. EverSource Wealth Advisors LLC grew its stake in shares of Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after acquiring an additional 1,565 shares in the last quarter. KBC Group NV purchased a new stake in shares of Adaptive Biotechnologies during the first quarter worth about $45,000. Assetmark Inc. increased its position in shares of Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after acquiring an additional 2,708 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new position in shares of Adaptive Biotechnologies in the fourth quarter worth about $51,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on ADPT. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. TD Cowen increased their target price on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. JPMorgan Chase & Co. lowered their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Finally, Guggenheim boosted their price target on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Adaptive Biotechnologies presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.50.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.